VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events PCSK9i access remains challenging in USA

From the Editors: PCSK9 inhibitors & cardiovascular disease: heralding a new therapeutic era

PCSK9 Forum Editors overview recent developments in PCSK9 science and therapeutics, culminating in regulatory approval of the first two PCSK9 monoclonal antibodies earlier this year. The editors highlight severe familial hypercholesterolaemia (FH, inherited high cholesterol), including homozygous FH, as a key priority. Additionally, there is a potential role for these novel agents in high-risk patients with established cardiovascular disease who cannot tolerate statin therapy.

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters